[en] The avenue of effective migraine therapies blocking calcitonin gene-related peptide (CGRP) transmission is the successful outcome of 35 years of translational research. Developed after short-acting, the small antagonists of the CGRP receptor (the "gepants"), the monoclonal antibodies blocking CGRP or its receptor (CGRP/rec mAbs) have changed the paradigm in migraine treatment. Contrary to the classical acute medications like triptans or nonsteroidal anti-inflammatory drugs (NSAIDs) with a transient effect, they act for long durations exclusively in the peripheral portion of the trigeminovascular system and can thus be assimilated to a durable attack treatment, unlike the classical preventives that chiefly act upstream on the central facets of migraine pathophysiology. Randomized controlled trials (RCT) of eptinezumab, erenumab, fremanezumab and galcanezumab have included collectively several thousands of patients, making them the most extensively studied class of preventive migraine treatments. Their results clearly indicate that CGRP/rec mAbs are significantly superior to placebo and have been comprehensively reviewed by Dodick [Cephalalgia 2019;39(3):445-458]. In this review we will briefly summarize the placebo-subtracted outcomes and number-needed-to-treat (NNT) of these pivotal RCTs and analyze new and post-hoc studies published afterwards focusing on effect size, effect onset and sustainability, response in subgroups of patients, safety and tolerability, and cost-effectiveness. We will also summarize our limited real-world experience with one of the CGRP/rec mAbs. Although methodological differences and lack of direct comparative trials preclude any reliable comparison, the overall impression is that there are only minor differences in efficacy and tolerability profiles between the four monoclonals: the average placebo-subtracted 50% responder rates for reduction in migraine headaches are 21.4% in episodic migraine (NNTs: 4-5), 17.4% in chronic migraine (NNTs: 4-8). Patients with an improvement exceeding 50% are rare, chronic migraineurs with continuous headache are unlikely to be responders and migraine auras are not improved. The effect starts within the first week after administration and is quasi maximal at one month. It is sustained for long time periods and may last for several months after treatment termination. CGRP/rec mAbs are effective even after prior preventive treatment failures and in patients with medication overuse, but the effect size might be smaller. They significantly reduce disability and health care resource utilization. The adverse effect profile of CGRP/rec mAbs is close to that of placebo with few minor exceptions and despite concerns related to the safeguarding role of CGRP in ischemia, no treatment-related vascular adverse events have been reported to date. Putting the CGRP/rec mAbs in perspective with available preventive migraine drug treatments, their major advantage seems not to be chiefly their superior efficacy but their unprecedented efficacy over adverse event ratio. Regarding cost-effectiveness, preliminary pharmaco-economic analyses of erenumab suggest that it is cost-effective for chronic migraine compared to no treatment or to onabotulinumtoxinA, but likely not for episodic migraine unless attack frequency is high, indirect costs are considered and its price is lowered.
Disciplines :
Neurology
Author, co-author :
SCHOENEN, Jean ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie (CHR)
MANISE, Maïté ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie (CHR)
Nonis, R; Headache Research Unit, Department of Neurology, University of Liège, Citadelle Hospital, 4000 Liège, Belgium
GERARD, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie (CHR)
Timmermans, Grégory ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
Language :
English
Title :
Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Tfelt-Hansen, P., Olesen, J., Taking the negative view of current migraine treatments. CNS Drugs 26:5 (2012), 375–382.
Hepp, Z., Dodick, D.W., Varon, S.F., Chia, J., Matthew, N., Gillard, P., et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37:5 (2017), 470–485.
Tfelt-Hansen, P., Diener, H.C., Steiner, T.J., Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: a mini-review. Cephalalgia 40:1 (2020), 122–126.
Dodick, D.W., CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia 39:3 (2019), 445–458.
Edvinsson, L., Haanes, K.A., Warfvinge, K., Krause, D.N., CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nat Rev Neurol 14:6 (2018), 338–350.
Hay, D.L., Garelja, M.L., Poyner, D.R., Walker, C.S., Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. Br J Pharmacol 175:1 (2018), 3–17.
Áfra, J., Sándor, P.S., Schoenen, J., Habituation of visual and intensity dependence of auditory evoked cortical potentials tend to normalize just before and during the migraine attack. Cephalalgia 20 (2000), 714–719.
Coppola, G., Di Renzo, A., Tinelli, E., Di Lorenzo, C., Di Lorenzo, G., Parisi, V., et al. Thalamo-cortical network activity during spontaneous migraine attacks. Neurology 87:20 (2016), 2154–2160.
Schulte, L.H., Mehnert, J., May, A., Longitudinal neuroimaging over 30 days: temporal characteristics of migraine. Ann Neurol 87:4 (2020), 646–651.
Schoenen, J., The pathophysiological conundrum of migraine. Jap J Head 44:2 (2017), 234–238.
Goadsby, P.J., Holland, P.R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., Akerman, S., Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 97:2 (2017), 553–622.
Lisicki, M., D'Ostilio, K., Coppola, G., Scholtes, F., Maertens de Noordhout, A., Parisi, V., et al. Evidence of an increased neuronal activation-to-resting glucose uptake ratio in the visual cortex of migraine patients: a study comparing 18FDG-PET and visual evoked potentials. J Headache Pain, 19(1), 2018, 49.
Gross, E.C., Lisicki, M., Fischer, D., Sándor, P.S., Schoenen, J., The metabolic face of migraine – from pathophysiology to treatment. Nat Rev Neurol 15:11 (2019), 627–643.
Burke, M.J., Joutsa, J., Cohen, A.L., Soussand, L., Cooke, D., Burstein, R., et al. Mapping migraine to a common brain network. Brain 143:2 (2020), 541–553.
Burstein, R., Noseda, R., Borsook, D., Migraine:, multiple processes, complex pathophysiology. J Neurosci 35:17 (2015), 6619–6629.
Ashina, M., Hansen, J.M., Do, T.P., Melo-Carrillo, A., Burstein, R., Moskowitz, M.A., Migraine and the trigeminovascular system – 40 years and counting. Lancet Neurol 18 (2019), 795–804.
Pellesi, L., Guerzoni, S., Pini, L.A., Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev 6:6 (2017), 534–547.
Johnson, K.W., Morin, S.M., Wroblewski, V.J., Johnson, M.P., Peripheral and central nervous system distribution of the CGRP neutralizing antibody [125I] galcanezumab in male rats. Cephalalgia 39:10 (2019), 1241–1248.
Chiarugi, A., A Popperian View on Anti-CGRP Biologics in Migraine. Headache 59:10 (2019), 1855–1860.
Kielbasa, W., Helton, D.L., A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia 39:10 (2019), 1284–1297.
Dodick, D.W., Lipton, R.B., Silberstein, S., Goadsby, P.J., Biondi, D., Hirman, J., et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia 39:9 (2019), 1075–1085.
Ashina, M., Saper, J., Cady, R., Schaeffler, B.A., Biondi, D.M., Hirman, J., et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40:3 (2020), 241–254.
Lipton, R.B., Goadsby, P.J., Smith, J., Schaeffler, B.A., Biondi, D.M., Hirman, J., et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology, 2020, 10.1212/WNL.0000000000009169 [pii: 10.1212/WNL.0000000000009169].
Deng, H., Li, G.G., Nie, H., Feng, Y.Y., Guo, G.Y., Guo, W.L., et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. BMC Neurol, 20(1), 2020, 57.
Goadsby, P.J., Reuter, U., Hallström, Y., Broessner, G., Bonner, J.H., Zhang, F., et al. A controlled trial of erenumab for episodic migraine. N Engl J Med 377:22 (2017), 2123–2132.
Dodick, D.W., Silberstein, S.D., Bigal, M.E., Yeung, P.P., Goadsby, P.J., Blankenbiller, T., et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319:19 (2018), 1999–2008.
Skljarevski, V., Matharu, M., Millen, B.A., Ossipov, M.H., Kim, B.K., Yang, J.Y., Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38:8 (2018), 1442–1454.
Tepper, S., Ashina, M., Reuter, U., Brandes, J.L., Doležil, D., Silberstein, S., Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:6 (2017), 425–434.
Silberstein, S.D., Dodick, D.W., Bigal, M.E., Yeung, P.P., Goadsby, P.J., Blankenbiller, T., et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377:22 (2017), 2113–2122.
Sakai, F., Takeshima, T., Tatsuoka, Y., Hirata, K., Lenz, R., Wang, Y., et al. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults. Headache 59:10 (2019), 1731–1742.
Rosen, N., Pearlman, E., Ruff, D., Day, K., Jim, N., agy, A., 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies. Headache 58:9 (2018), 1347–1357.
Steiner, T.J., Tfelt-Hansen, P., Misused and misleading: “100% Response Rate” to galcanezumab in patients with episodic migraine. Headache, 59(4), 2019, 626.
Brandes, J.L., Diener, H.C., Dolezil, D., Freeman, M.C., McAllister, P.J., Winner, P., et al. The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response. Cephalalgia 40:1 (2020), 28–38.
Halker Singh, R.B., Aycardi, E., Bigal, M.E., Loupe, P.S., McDonald, M., Dodick, D.W., Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials. Cephalalgia 39:1 (2019), 52–60.
Schwedt, T., Reuter, U., Tepper, S., Ashina, M., Kudrow, D., Broessner, G., et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain, 19(1), 2018, 92.
Silberstein, S.D., Rapoport, A.M., Loupe, P.S., Aycardi, E., McDonald, M., Yang, R., et al. The effect of beginning treatment with fremanezumab on headache and associated symptoms in the randomized phase 2 study of high frequency episodic migraine: post-hoc analyses on the first 3 weeks of treatment. Headache 59:3 (2019), 383–393.
Winner, P.K., Spierings, E.L.H., Yeung, P.P., Aycardi, E., Blankenbiller, T., Grozinski-Wolff, M., et al. Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine. Headache 59:10 (2019), 1743–1752.
Goadsby, P.J., Dodick, D.W., Martinez, J.M., Ferguson, M.B., Oakes, T.M., Zhang, Q., et al. Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. J Neurol Neurosurg Psychiatry 90:8 (2019), 939–944.
Detke, H.C., Millen, B.A., Zhang, Q., Samaan, K., Ailani, J., Dodick, D.W., et al. Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the evolve studies. Headache 60:2 (2020), 348–359.
Förderreuther, S., Zhang, Q., Stauffer, V.L., Aurora, S.K., Láinez, M.J.A., Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain, 19(1), 2018, 121.
Reuter, U., Goadsby, P.J., Lanteri-Minet, M., Wen, S., Hours-Zesiger, P., Ferrari, M.D., et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392:10161 (2018), 2280–2287.
Ferrari, M.D., Diener, H.C., Ning, X., Galic, M., Cohen, J.M., Yang, R., et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394:10203 (2019), 1030–1040.
Ashina, M., Tepper, S., Brandes, J.L., Reuter, U., Boudreau, G., Dolezil, D., et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 38:10 (2018), 1611–1621.
Goadsby, P.J., Paemeleire, K., Broessner, G., Brandes, J., Klatt, J., Zhang, F., et al. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 39:7 (2019), 817–826.
Ruff, D.D., Ford, J.H., Tockhorn-Heidenreich, A., Sexson, M., Govindan, S., Pearlman, E.M., et al. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. Cephalalgia 39:8 (2019), 931–944.
Ailani, J., Pearlman, E., Zhang, Q., Nagy, A.J., Schuh, K., Aurora, S.K., Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies. Eur J Neurol 27:3 (2020), 542–549.
Silberstein, S.D., Stauffer, V.L., Day, K.A., Lipsius, S., Wilson, M.C., Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain, 20(1), 2019, 118.
Tepper, S.J., Diener, H.C., Ashina, M., Brandes, J.L., Friedman, D.I., Reuter, U., et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92:20 (2019), e2309–e2320.
Ford, J.H., Foster, S.A., Stauffer, V.L., Ruff, D.D., Aurora, S.K., Versijpt, J., Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine. Patient Prefer Adherence 12 (2018), 2413–2424.
Buse, D.C., Lipton, R.B., Hallström, Y., Reuter, U., Tepper, S.J., Zhang, F., et al. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia 38:10 (2018), 1622–1631.
VanderPluym, J., Dodick, D.W., Lipton, R.B., Ma, Y., Loupe, P.S., Bigal, M.E., Fremanezumab for preventive treatment of migraine: functional status on headache-free days. Neurology 91:12 (2018), e1152–e1165.
Ashina, M., Goadsby, P.J., Reuter, U., Silberstein, S., Dodick, D., Rippon, G.A., et al. Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia 39:11 (2019), 1455–1464.
Ashina, M., Kudrow, D., Reuter, U., Dolezil, D., Silberstein, S., Tepper, S.J., et al. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia 39:14 (2019), 1798–1808.
Kudrow, D., Pascual, J., Winner, P.K., Dodick, D.W., Tepper, S.J., Reuter, U., et al. Vascular safety of erenumab for migraine prevention. Neurology 94:5 (2020), e497–e510.
Paemeleire, K., Louis, P., Magis, D., Vandenheede, M., Versijpt, J., Vandersmissen, B., et al. Diagnosis, pathophysiology and management of chronic migraine: a proposal of the Belgian Headache Society. Acta Neurol Belg 115:1 (2015), 1–17.
Birlea, M., Penning, S., Callahan, K., Schoenen, J., Efficacy and safety of external trigeminal neurostimulation in the prevention of chronic migraine: an open-label trial. Cephalalgia Rep 2 (2019), 1–10.
Buch, D., Chabriat, H., Lamotrigine in the prevention of migraine with aura: a narrative review. Headache 59:8 (2019), 1187–1197.
Christensen, C.E., Younis, S., Deen, M., Khan, S., Ghanizada, H., Ashina, M., Migraine induction with calcitonin gene-related peptide in patients from erenumab trials. J Headache Pain, 19(1), 2018, 105.
Ziegeler, C., May, A., Non-responders to treatment with antibodies to the CGRP-Receptor may profit from a switch of antibody class. Headache 60:2 (2020), 469–470.
Raffaelli, B., Mussetto, V., Israel, H., Neeb, L., Reuter, U., Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain, 20(1), 2019, 66.
Sacco, S., Bendtsen, L., Ashina, M., Reuter, U., Terwindt, G., Mitsikostas, D.D., European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain, 20(1), 2019, 6.
Deen, M., Correnti, E., Kamm, K., Kelderman, T., Papetti, L., Rubio-Beltrán, E., European Headache Federation School of Advanced Studies (EHF-SAS). Blocking CGRP in migraine patients – a review of pros and cons. J Headache Pain, 18(1), 2017, 96.
Xu, D., Chen, D., Zhu, L.N., Tan, G., Wang, H.J., Zhang, Y., et al. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials. Cephalalgia 39:9 (2019), 1164–1179.
MaassenVanDenBrink, A., Meijer, J., Villalón, C.M., Ferrari, M.D., Wiping Out CGRP: Potential Cardiovascular Risks. Trends Pharmacol Sci 37:9 (2016), 779–788.
Depre, C., Antalik, L., Starling, A., Koren, M., Eisele, O., Lenz, R.A., et al. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina. Headache 58:5 (2018), 715–723.
Favoni, V., Giani, L., Al-Hassany, L., Asioli, G.M., Butera, C., de Boer, I., European Headache Federation School of Advanced Studies (EHF-SAS). CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?. J Headache Pain, 20(1), 2019, 27.
Noseda, R., Schain, A.J., Melo-Carrillo, A., Tien, J., Stratton, J., Mai, F., et al. Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier. Cephalalgia 40:3 (2020), 229–240.
Changeux, J.P., Duclert, A., Sekine, S., Calcitonin gene-related peptides and neuromuscular interactions. Ann N Y Acad Sci 657 (1992), 361–378.
Sample, S.J., Heaton, C.M., Behan, M., Bleedorn, J.A., Racette, M.A., Hao, Z., et al. Role of calcitonin gene-related peptide in functional adaptation of the skeleton. PLoS One, 9(12), 2014, e113959.
Szperka, C.L., VanderPluym, J., Orr, S.L., Oakley, C.B., Qubty, W., Patniyot, I., et al. Recommendations on the use of anti-CGRP monoclonal antibodies in children and adolescents. Headache 58:10 (2018), 1658–1669.
Bussone, G., Diener, H.C., Pfeil, J., Schwalen, S., Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 59:8 (2005), 961–968.
Vo, P., Wen, S., Martel, M.J., Mitsikostas, D., Reuter, U., Klatt, J., Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed. Cephalalgia 39:5 (2019), 608–616.
Mitsikostas, D.D., Rapoport, A.M., New players in the preventive treatment of migraine. BMC Med, 13, 2015, 279.
Grazzi, L., Rizzoli, P., Acceptance and Commitment Therapy (ACT) vs Erenumab for High Frequency Episodic Migraine Without Aura: Time to Take the Gloves Off!. Headache, 2020, 10.1111/head.13776.
Schoenen, J., Vandersmissen, B., Jeangette, S., Herroelen, L., Vandenheede, M., Gérard, P., et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology 80 (2013), 697–704.
Lipton, R.B., Brennan, A., Palmer, S., Hatswell, A.J., Porter, J.K., Sapra, S., et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ 21:7 (2018), 666–675.
Sussman, M., Benner, J., Neumann, P., Menzin, J., Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia 38:10 (2018), 1644–1657.
Giannouchos, T.V., Mitsikostas, D.D., Ohsfeldt, R.L., Vozikis, A., Koufopoulou, P., Cost-effectiveness analysis of erenumab versus onabotulinumtoxina for patients with chronic migraine attacks in Greece. Clin Drug Investig 39:10 (2019), 979–990.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
